EGFR and cancer: AURKB, in combination with EGFR knockdown, have shown enhanced therapeutic effect by inhibiting PC3 cell proliferation and inducing apoptosis in vitro, whereas androgen-dependent cancer cells, LNCaP, remain unaffected by the endogenous expression levels [32].